Clinical trials: Primary Open - Angle Glaucoma (POAG)
Primary Open Angle Glaucoma
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma
To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).
- Trial name
- NCT06991270
- Testing
- OMNI 3.0 Surgical System
- Where
- Panama
- Volunteers
- 25 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07168902
- Testing
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Primary Open Angle
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a…
- Trial name
- NCT04737928
- Testing
- Latanoprost, tafluprost
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
Primary Open Angle Glaucoma (POAG), Ocular Hypertension
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
- Trial name
- NCT07335211
- Testing
- HUC3-637, HUC3-637-R
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- Huons Co., Ltd.
Glaucoma, Open-angle, Ocular Hypertension
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and…
- Trial name
- NCT03293992
- Testing
- 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Open-angle Glaucoma, Ocular Hypertension
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
- Trial name
- SEE-1 (NCT02179008)
- Testing
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Primary Open Angle Glaucoma, Healthy Subjects
Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor
The objectives of this study are to assess the safety and effectiveness of the SENSIMED Triggerfish® (TF) device in continuous recording of relative fluctuation in intraocular pressure (IOP).
- Trial name
- NCT01390779
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
Primary Open Angle Glaucoma (POAG)
Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.
- Trial name
- NCT01252849
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in adults.
- Trial name
- NCT04284514
- Testing
- AKB-9778 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Aerpio Therapeutics
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Primary Open Angle Glaucoma
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
- Trial name
- EVOLVE (NCT06407973)
- Testing
- OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sight Sciences, Inc.
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Primary objective: The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01% and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse…
- Trial name
- NCT02017327
- Testing
- Monoprost, Lumigan 0.01%, Lumigan 0.03% Unit Dose
- Where
- France
- Volunteers
- 379 people
- Sponsor
- Laboratoires Thea
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Glaucoma, Glaucoma, Open-Angle
Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor
A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor
- Trial name
- NCT05127551
- Testing
- iStent Infinite, Competitor Device
- Where
- Canada
- Volunteers
- 179 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an…
- Trial name
- NCT00759239
- Testing
- Travoprost 0.004% / Timolol maleate 0.5%
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Alcon Research